| http://www.w3.org/ns/prov#value | - The pharmaceutical industry would be loath to do it, because they risk finding their drug is less efficient.According to Bousquet, certain European countries, including France and the UK, already require studies that include a broad swath of patients for many new drugs.For many diseases this might be important, he said.
|
